21

22
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, August 18, 1998: US05795889 (33 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


23
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Aventis Pharmaceuticals, Raymond S Parker III, Peter J Butch, November 11, 2003: US06645969 (31 worldwide citation)

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


24
William R Ewing, Michael R Becker, Henry W Pauls, Daniel L Cheney, Jonathan S Mason, Alfred P Spada: Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, Martin F Savitzky, James A Nicholson, March 18, 1997: US05612353 (28 worldwide citation)

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to co ...


25
Alfred P Spada, William L Studt, Henry F Campbell, Donald E Kuhla, Thomas Tucker: Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses. Rorer Pharmaceutical Corporation, September 12, 1989: US04866074 (20 worldwide citation)

This invention relates to substituted pyridooxazinone and naphtheridone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.


26
Alfred P Spada, William L Studt, Henry F Campbell, Donald E Kuhla: Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses. Rorer Pharmaceutical Corporation, April 18, 1989: US04822794 (18 worldwide citation)

This invention relates to substituted pyridooxazinone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.


27
Michael R Myers, Alfred P Spada, Paul E Persons, Martin P Maguire: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases. Aventis Pharmaceuticals, Synnestvedt & Lechner, January 25, 2005: US06846815 (16 worldwide citation)

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to diso ...


28
William R Ewing, Michael R Becker, Yong Mi Choi Sledeski, Heinz W Pauls, Daniel G McGarry, Roderick S Davis, Alfred P Spada: Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds. Rhone Poulenc Rorer Pharmaceuticals, Rose J Oehler, March 7, 2000: US06034093 (11 worldwide citation)

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invent ...


29

30
Alfred P Spada, Paul E Persons, Alexander Levitzki, Chaim Gilon, Aviv Gazit: Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Synnestvedt & Lechner, August 12, 1997: US05656655 (10 worldwide citation)

A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a pharmaceutically effective amount of a pharmaceutical composition containing, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutical ...